Lupin receives tentative approval from U.S. FDA for Apalutamide Tablets

Global pharma major Lupin Limited (Lupin) has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Apalutamide Tablets, 60 mg, to market a generic equivalent of Erleada® Tablets, 60 mg of Janssen Biotech, Inc. This product will be manufactured at Lupin's Pithampur facility in India.

Apalutamide Tablets, 60 mg, (RLD Erleada®) had estimated annual sales of USD 1,185.5 million in the U.S. (IQVIA MAT July 2023).

Shares of Lupin Limited was last trading in BSE at Rs. 1188.90 as compared to the previous close of Rs. 1171.80. The total number of shares traded during the day was 23724 in over 1637 trades.

The stock hit an intraday high of Rs. 1191.80 and intraday low of 1166.35. The net turnover during the day was Rs. 28010742.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 USFDA TentativeApproval ApalutamideTablets